The purpose of this study was to investigate the feasibility of incorporating linear energy transfer (LET) 16 into the optimization of intensity modulated proton therapy (IMPT) plans. Because increased LET 17 correlates with increased biological effectiveness of protons, high LETs in target volumes and low LETs 18 in critical structures and normal tissues are preferred in an IMPT plan. However, if not explicitly 19 incorporated into the optimization criteria, different IMPT plans may yield similar physical dose 20 distributions but greatly different LET, specifically dose-averaged LET, distributions. Conventionally, the 21 IMPT optimization criteria (or cost function) only includes dose-based objectives in which the relative 22 biological effectiveness (RBE) is assumed to have a constant value of 1.1. In this study, we added LET-23 based objectives for maximizing LET in target volumes and minimizing LET in critical structures and 24 normal tissues. Due to the fractional programming nature of the resulting model, we used a variable 25 reformulation approach so that the optimization process is computationally equivalent to conventional 26 IMPT optimization. In this study, five brain tumor patients who had been treated with proton therapy at 27 our institution were selected. Two plans were created for each patient based on the proposed LET-28 incorporated optimization (LETOpt) and the conventional dose-based optimization (DoseOpt). The 29 optimized plans were compared in terms of both dose (assuming a constant RBE of 1.1 as adopted in 30 clinical practice) and LET. Both optimization approaches were able to generate comparable dose 31 distributions. The LET-incorporated optimization achieved not only pronounced reduction of LET values 32 in critical organs, such as brainstem and optic chiasm, but also increased LET in target volumes, 33 compared to the conventional dose-based optimization. However, on occasion, there was a need to 34 tradeoff the acceptability of dose and LET distributions. Our conclusion is that the inclusion of LET-35 dependent criteria in the IMPT optimization could lead to similar dose distributions as the conventional 36 optimization but superior LET distributions in target volumes and normal tissues. This may have 37 substantial advantage in improving tumor control and reducing normal tissue toxicities. 38 39
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Introduction 40
In clinical practice, proton therapy treatments to date have been prescribed at physical doses 10% lower 41 than those used in photon therapy. This paradigm is based on an assumption that doses deposited by 42 protons are 10% more biologically effective than those by photons. In other words, the relative biological 43 effectiveness (RBE) of protons versus photons is considered to have a constant value of 1.1. However, it 44 is known that RBE is a complex variable dependent on many factors, including dose per fraction, linear 45 energy transfer (LET), tissue type, biological endpoint, etc. Nevertheless, proton therapy practitioners 46 continue to use the simplistic constant RBE due, in part, to the lack of reliable and accurate predictive 47 RBE models (Paganetti et al., 2002) . 48
49
The LET, defined as the average energy transfer (ionization) per unit distance traveled by charged 50 primary particles (ICRU, 2011) , increases slowly at first and then exponentially near the end of proton 51 range. It is shown that increased LET leads to increased RBE, especially at the end of range of protons 52 (Wilkens and Oelfke, 2004; Guan et al., 2015a) , where the RBE value can be 1.3 or higher at the Bragg 53 peak and 1.6 or higher in the fall off region (in a few millimeters). Precautions in this respect have been 54 taken into account in current proton treatment planning by avoiding the use of beams whose distal edge 55 may end up in or close to a critical structures. In this way, the possible overshooting due to uncertainties 56 in dose distributions and the resulting damage of high LET/RBE protons to healthy tissues could be 57 prevented. However, this measure may prevent the selection of potentially beneficial beam angles and 58 could diminish the therapeutic value of proton therapy. 59
60
In passively scattered proton therapy (PSPT) and single field optimized intensity modulated proton 61 therapy (SFO-IMPT), high LET protons at the distal edge of each beam are unavoidably placed in normal 62 tissues just beyond the distal edges of target volumes. In multiple field optimized intensity modulated 63 proton therapy (MFO-IMPT), denoted as IMPT hereafter, intensities of beamlets from all incident beams 64 are simultaneously optimized to meet dosimetric requirements. IMPT thus has much higher degree of 65 Page 3 of 22  AUTHOR SUBMITTED MANUSCRIPT -PMB-106298.R1   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 A c c e p t e d M a n u s c r i p t freedom for modulation than PSPT and SFO-IMPT. Previous studies have shown that highly modulated 66 fields in IMPT can produce equivalent physical dose distributions but greatly different LET distributions 67 (Grassberger et al., 2011; Giantsoudi et al., 2013) clinically. This may be due to the reluctance to accept the resulting physical dose (i.e., RBE of 1.1) 75 distributions from such methods, which may not be consistent with conventional practice. However, 76 recent clinical data have reported unforeseen normal tissue complications from proton treatments (Sabin 77 et al., 2013; Gunther et al., 2015) and their positive correlation with high LETs (Peeler et al., 2016) . 78
Subsequently, considering the RBE dependence on LET in treatment planning while preserving the 79 physical dose prescribed in current practice has been focused in recent studies (Bassler et al., 2010; 80 Giantsoudi et al., 2013; Bassler et al., 2014; Fager et al., 2015; Unkelbach et al., 2016) . We will discuss 81 these methods in the Discussion section. 82
83
The present study aimed to investigate the impact of incorporating LET criteria directly into IMPT 84 optimization. Both dose and LET distributions could be optimized simultaneously in the proposed 85 approach. Dose-averaged LET was used to indicate LET values in this study. The goal of this 86 optimization was set to not only produce satisfactory dose distributions but also to achieve reduced LET 87 distributions (thus lower biologically effective dose distributions) in critical structures and increased LET 88 in target volumes compared to plans created using conventional objectives. 89 90 91 A c c e p t e d M a n u s c r i p t
Methods and materials 92

LET-incorporated Optimization 93
The goal of LET-incorporated IMPT optimization in this study was to optimize dose and LET 94 distributions simultaneously. The objectives and constraints on doses were consistent with those used in 95 conventional IMPT optimization. The calculation and planning criteria of dose here implicitly included a 96 RBE of 1.1, as in current clinical practice. The optimization of variable RBE was not within the scope of 97 this study. The additive objectives of LET were, straightforwardly, maximization of LET in tumor targets 98 and minimization of LET in critical tissues and normal tissues. 99
100
Given that ‫ܦ‬ and ‫ܮ‬ indicate the dose and LET contribution, respectively, from beamlet ݆ to voxel ݅ in 101 unit intensity and ‫ݓ‬ indicates the intensity of beamlet ݆, the total dose ‫ܦ‬ and dose-averaged LET 102
104
(2) 105
106
The calculation of ‫ܦ‬ and ‫ܮ‬ was carried out by a previously validated fast Monte Carlo system (Yepes 107 et al., 2016) . Although LET is typically quantified in two averaging variants, i.e., track-averaged and 108 dose-averaged LET (Grassberger and Paganetti, 2011; Guan et al., 2015b) , only the latter was used in this 109 study for consistency with most biological dosimetric analyses. 110
111
The general optimization model in radiation therapy including IMPT can be represented as follows in (3)-112 A c c e p t e d M a n u s c r i p t
The minimization cost function is formulated by the deviation between the delivered ‫ܦ(‬ ) and prescribed 117 ‫ܦ(‬ ) doses of each voxel. Also a priority factor (ߣ ሻ is assigned to each voxel or structure in order to 118 control the tradeoff between competing objectives. The lower and upper bounds of the doses are ‫ܤܮ‬ and 119 ‫ܤܷ‬ , which are adjusted for different structures and specific applications. It has been established that 120 quadratic (i.e., ‫‬ = 2) and linear (i.e., ‫‬ = 1) forms of the cost function (3) are effective in optimizing 121 dose distributions for radiation therapy (Bortfeld, 1999; Chan et al., 2006; Jia et al., 2011; Cao et al., 122 2013) . In this study, a linear cost function (6) was used for performing the conventional dose-based 123 optimization (DoseOpt): 124
where ܶ, ܱ, ܰ are the set of voxels in target volumes, organs at risk (OARs), and normal tissues, 126 respectively. Optimization priority factors for penalizing over-dosing and under-dosing on target, OAR 127 doses over the limit ‫ܦ‬ ∈ை ௫ , and normal tissue doses are ߣ ் ା , ߣ ் ି , ߣ ை , and ߣ ே , respectively. 128
129
By adding two terms for maximizing dose-averaged LET in the target and minimizing it in OARs, the 130 cost function for LET-incorporated optimization (LETOpt) was formulated as shown in (7). The 131 optimization priority factors for the two objectives are ߠ ் and ߠ ை . 132
Note that threshold LET values and objectives for normal tissue LETs were not used in this study, but 134 they can be easily added for applications. Constraints on doses were identical in DoseOpt and LETOpt. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 A c c e p t e d M a n u s c r i p t the linearity, the problem is quasiconvex and can be conveniently reformulated to a linear programming 140 (8) 146
147
The reformulated LP model of LETOpt thus has an optimization variable ‫ݔ‬ , instead of the original 148 beamlet intensity ‫ݓ‬ , and an auxiliary variable ‫.ݐ‬ Meanwhile, the dose constraints defined by ‫ݓ‬ are 149 changed to ones such as 150
After solving the reformulated LP for LETOpt, i.e., (8)-(10), and obtaining the optimal solution of ‫ݔ‬ , the 153 beamlet intensity can be post-processed using ‫ݓ‬ = ‫ݔ‬ ‫ݐ‬ ⁄ for the final dose and LET d calculation. In this 154 study, both DoseOpt and LETOpt models were solved by the interior point method using a commercial 155 solver CPLEX v12.3 (IBM, NY, USA). 156 157
Patients and Treatment Planning 158
Five brain tumor patients that had been treated with proton therapy (PSPT or SFO-IMPT) at our 159 institution were selected for this study, including one glioblastoma, one anaplastic astrocytoma and three 160 ependymoma cases. Although the tumor size and location varied from one patient to another, in all cases, 161 one or more critical structures, e.g., brainstem or optic chiasm, were adjacent to or overlapped with gross 162 target volumes (GTVs) and clinical target volumes (CTVs). The prescriptions to target volumes and field 163 arrangements were the same as those used in the clinical treatments. The doses prescribed to all OARs are 164 A c c e p t e d M a n u s c r i p t set to zero in optimization. Table 1 lists patient information and specific treatment planning parameters 165 for the five patient cases. 166 167 Two IMPT plans were created for each patient case, one using the conventional dose-based optimization 168 and the other using the proposed LET-incorporated optimization. Each plan was based on 3D modulation 169 delivery (Lomax, 1999) . The intensities of all beamlets from all treatment fields were simultaneously and 170 independently optimized, that is, MFO was applied. The simulation of plan delivery and dose/LET 171 distributions was based on a discrete pencil beam scanning system commissioned at our institution (Gillin 172 et al., 2010) . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 A c c e p t e d M a n u s c r i p t respectively. The maximum and mean LET d for the optic chiasm were reduced by 21.1% and 21.9%, 191 respectively, and the LET d for 1% and 99% of the GTV were increased by 27.2% and 18.4%. for LETOpt plan 2. In other words, plan 1 was optimized with ten times less priority given to dose 210 objectives, including ones for target volumes and critical normal tissues, than plan 2. For plan 1, although 211 the brainstem was not well spared at low doses by LETOpt compared to DoseOpt, its exposure to high 212
LETs was greatly reduced with a decrease of 3 ܸ݇݁/ߤ݉ from the maximum LET d . Note that the similar 213 behavior was observed in Patient 4 and 5. For plan 2, the dose sparing of the brainstem was similar for 214
LETOpt and DoseOpt, but the benefit of LET sparing could not be achieved as it was in plan 1. 215
Pronounced increases of LET d in target volumes were achieved by both LETOpt plans. However, the 216 A c c e p t e d M a n u s c r i p t magnitude of increase was modestly lower for plan 2 than for plan 1 because higher optimization priority 217 was given to dose instead of LET in plan 2. The choice between plan 1 and 2 in clinic should be 218 determined by physician's preference on different metrics such as maximum or mean dose to brainstem, 219 and boost in target dose, etc. We should note that the tradeoff effect between dose and LET metrics was 220 observed in all patient cases, while its magnitude and sensitivity to changing optimization priorities varied 221 among cases (as seen in examples shown in Figure 1, 2 and 4) . 222 223
Discussion 224
Proton therapy is increasingly accessible to cancer patients (Chang et al., 2014; Schuemann et al., 2014) . 225
Continuous improvement of this cutting-edge technology, including treatment planning, will allow its 226 theoretical benefits to be fully realized and its associated risks to be minimized. Currently, the biological 227 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 A c c e p t e d M a n u s c r i p t studies, is expected to boost the differential benefits of increasing the biological effect of protons in tumor 243 and/or reducing it in healthy tissues compared to the current standard for brain tumor cases. Within dose-244 exposed volumes, evaluation of LET can be used as another measure of plan quality, in addition to dose. 245
Moreover, one can also choose to use radiobiological models as additional indicators of plan quality, such 246 as the linear quadratic (LQ) cell survival model, tumor control probability (TCP), normal tissue 247 complication probability (NCTP), and RBE models. For example, Figure 3 shows the DVHs from 248 variable RBE-weighted doses based on a recently published RBE model (McNamara et al., 2015) for a 249 representative case (Patient 1). This demonstrates that the LET-incorporated optimization not only 250 increased the variable RBE-weighted dose for target volumes but also reduced it for critical structures 251 compared to a plan conventionally optimized using constant RBE. Similar DVHs for other patient cases 252 can be found in Appendix B. 253 254 LET painting approaches have been investigated for ion (Bassler et al., 2010; Bassler et al., 2014) and 255 proton (Fager et al., 2015) therapies, in which planning methods such as splitting targets or adopting 256 opposite beam arrangements are used to allocate the high LET protons within target instead of normal 257 tissues. However, those techniques may require greater effort in planning, quality assurance, and delivery 258 than does the current practice because they use more planning volumes and beam angles. In contrast, 259 incorporating LET directly into the optimization process may have certain practical advantages over the 260 LET painting techniques and it could be easily implemented in clinical settings. Such an approach as 261 presented in this work can adopt the same target volumes and beam arrangements that are used in 262 conventional PSPT and IMPT treatment plans. Meanwhile, ideas in LET painting such as avoiding the 263 distal edge in target boundary regions could be used to improve the benefits of LET-incorporated 264
optimization. 265 266
One recent study discussed a multi criteria optimization approach in which a set of IMPT plans were 267 created using various dose based objectives and constraints, then plans with superior dose and LET 268
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272
In another recent study, a two-step prioritized optimization approach was proposed: first a plan was 273 optimized using conventional dose criteria, and, in the second step, the plan was optimized solely based 274 on the product of LET and dose as a surrogate of variable RBE weighted dose with constraints to limit the 275 change to physical dose distribution from the first step (Unkelbach et al., 2016) . Prioritized optimization 276 may be an effective approach to managing the trade-off effect between dose and LET. However, the 277 optimality of LET optimization may be affected by the local minimum problem in nonconvex 278 optimization, as the second round of prioritized optimization uses a warm start. This is less of a problem 279 for simultaneous optimization approaches such as the one proposed in this study. However, our approach 280 has the drawback of requiring determination of good optimization priority factors to balance gains in dose 281 and LET. The comparison of the effectiveness and efficiency of different optimization strategies is also of 282 interest and will be an area of future study. 283
284
Our study confirms that the redistributed LET maps may compensate the cut of quality dose distributions 285 achieved by IMPT (Unkelbach et al., 2016) . This was seen in Patient 3 and 5 where brainstem dose was 286 increased in the LET optimized plans at the low dose region compared to the dose optimized plan. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 A c c e p t e d M a n u s c r i p t 295
Conclusion 296
In this study, a LET-incorporated IMPT optimization method was introduced. This method was able to 297 produce clinically satisfactory dose distributions while increasing dose-averaged LET in target volumes 298 and reducing it in critical normal tissues for five selected brain tumor patient cases. The clinical 299 application of this method requires no changes to the current treatment protocols using a constant RBE 300 and therefore has a potential to bring an immediate improvement to IMPT in enhancing tumor control and 301 reducing normal tissue toxicities. 302
303
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